

International Application .: PCT/EP00/01468 Attorney Docket No.: BM45378

Al matid

30. An isolated polynucleotide encoding a polypeptide of Claim 29 or the full complement to the isolated polynucleotide.

- 31. The isolated polypeptide of claim 25, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.
- 32. The isolated polypeptide of Claim 25 wherein the isolated polypeptide of (a) consists of one of SEQ ID NOs: 2 or 4.
- 33. An isolated polynucleotide encoding a polypeptide of Claim 32 or the full complement to the isolated polynucleotide.
- 34. A process for expressing the polynucleotide of Claim 33 comprising transforming a host cell with an expression vector comprising the polynucleotide and culturing the host cell under conditions sufficient for expression of the polynucleotide.
- 35. A fusion protein comprising the isolated polypeptide of Claim 25.
- 36. An isolated polynucleotide comprising the polynucleotide of one of SEQ ID NOs:1 or 3.
- 37. An isolated polynucleotide segment comprising a polynucleotide sequence or the full complement of the entire length of the polynucleotide sequence, wherein the polynucleotide sequence hybridizes to the full complement of one of SEQ ID NOs:1 or 3 minus the complement of any stop codon, wherein the hybridization conditions include incubation at 42 °C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing in 0.1x SSC at 65°C; and, wherein the polynucleotide sequence is identical to one of SEQ ID NOs:1 or 3 minus any terminal stop codon, except that, over the entire length corresponding to one of SEQ ID NOs:1 or 3 minus any terminal stop codon, \mathbf{n}_n nucleotides are substituted, inserted or deleted, wherein \mathbf{n}_n satisfies the following expression

International Application ...: PCT/EP00/01468 Attorney Docket No.: BM45378

$$n_n \leq x_n - (x_n \bullet y)$$

f/ cont'd wherein \mathbf{x}_n is the total number of nucleotides in one of SEQ ID NOs:1 or 3 minus any terminal stop codon, \mathbf{y} is at least 0.95, and wherein any non-integer product of \mathbf{x}_n and \mathbf{y} is rounded down to the nearest integer before subtracting the product from \mathbf{x}_n ; and wherein the polynucleotide sequence detects *Moraxella catarrhalis*.

- 38. An expression vector comprising the isolated polynucleotide of Claim 26.
- 39. A host cell transformed with the expression vector of Claim 38.
- 40. A vaccine comprising the polypeptide of Claim 25 and a pharmaceutically acceptable carrier.
- 41. The vaccine of Claim 40, wherein the vaccine comprises at least one other *Moraxella* catarrhalis antigen.
- 42. An antibody immunospecific for the polypeptide or immunogenic fragment of Claim 25.
- 43. A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 25.
- 44. A method of diagnosing a *Moraxella catarrhalis* infection, comprising identifying a polypeptide of Claim 25, or an antibody that is immunospecific for the polypeptide, present within a biological sample from an animal suspected of having such an infection.
- 45. A method for inducing an immune response in a mammal comprising administration of the isolated polynucleotide of Claim 26.
- 46. A therapeutic composition useful in treating humans with *Moraxella catarrhalis* comprising at least one antibody directed against the polypeptide of claim 25 and a suitable pharmaceutical carrier.